Yes, Vraylar (cariprazine) is FDA-approved for adjunctive treatment of major depressive disorder in adults and demonstrates clinically meaningful efficacy.
Vraylar is FDA-approved as an adjunctive therapy (added to antidepressants) for treating major depressive disorder (MDD) in adults 1. This approval is specifically for patients who have had an inadequate response to antidepressant monotherapy.
FDA Approval Status
Vraylar received FDA approval for adjunctive treatment of MDD based on two pivotal phase 3 trials 1. The approved indication is clear: along with antidepressant medicines to treat major depressive disorder (MDD) in adults 1. It is NOT approved as monotherapy for MDD—it must be used in combination with an ongoing antidepressant.
Efficacy Evidence
The efficacy data supporting this approval is robust:
Study 10 (N=751): Cariprazine 1.5 mg/day + antidepressant showed statistically significant superiority over placebo + antidepressant, with a placebo-subtracted difference of -2.5 points on the MADRS scale (95% CI: -4.2 to -0.9) at week 6 1
Study 11 (N=808): Cariprazine 2-4.5 mg/day (mean 2.6 mg) + antidepressant demonstrated significant benefit with a placebo-subtracted difference of -2.2 points (95% CI: -3.7 to -0.6) at week 8 1
The most recent meta-analysis (2026) comparing all FDA-approved adjunctive antipsychotics for MDD found that lumateperone had the highest efficacy, followed by aripiprazole, brexpiprazole, cariprazine, and quetiapine XR 2. Cariprazine showed moderate efficacy (RR 1.20; 95% CrI 1.07-1.36) but better acceptability than some alternatives 2.
Optimal Dosing Strategy
Start with cariprazine 1.5 mg/day, as this dose demonstrated the most consistent efficacy across trials 1, 3. The 3 mg dose showed less consistent results and was not statistically significant in one of the pivotal trials 1. Early improvement by week 2 predicts continued response through 6 weeks 4.
Clinical Considerations
Who benefits most:
- Women showed greater improvement (β = -0.190, p = 0.006) 4
- Patients using SSRIs as their baseline antidepressant (β = -0.478, p < 0.001) 4
- Those with higher baseline depression severity (β = -0.075, p < 0.001) 4
- Patients with less severe baseline anxiety symptoms responded better 4
Monitoring strategy:
- Assess response at week 2—early improvement predicts continued benefit 4
- If no improvement by weeks 6-8, consider switching strategies per standard MDD guidelines 5
- Monitor for akathisia and nausea (most common adverse events at >5% and twice placebo rate) 3
Safety Profile
Metabolic effects are minimal: Weight gain was statistically significant but generally not clinically meaningful, with no significant changes in fasting glucose, triglycerides, or cholesterol compared to placebo 6. This represents a favorable metabolic profile compared to other atypical antipsychotics.
Acceptability: Cariprazine showed moderate acceptability (RR 1.44; 95% CrI 1.15-1.82), ranking third among FDA-approved adjunctive antipsychotics, better than quetiapine XR and lumateperone but slightly worse than aripiprazole and brexpiprazole 2.
Real-World Effectiveness
Real-world data confirms trial findings: patients with MDD receiving adjunctive cariprazine showed mean PHQ-9 reductions of 3.5 points at 2 months, 4.1 points at 6 months, and 3.7 points at 12 months, demonstrating sustained benefit 7.
Critical Caveats
- Black box warning: Increased risk of suicidal thoughts/actions in patients ≤24 years, especially in first few months or with dose changes 1
- Not approved for monotherapy in MDD—must be used with an antidepressant 1
- Not approved for children with MDD 1
- The 3 mg dose offers no clear advantage over 1.5 mg and may have worse tolerability 1, 3